Date: 2017-11-30
Type of information: Opening of new premises
Compound: new facility in the San Francisco Bay Area
Company: Orchard Therapeutics (UK)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On November 30, 2017, Orchard Therapeutics announced the opening of a second facility for technical operations in the San Francisco Bay Area. In combination with the existing Foster City site, the new facility located at 1360 O’Brien Drive, Menlo Park, Calif., quadruples Orchard’s laboratory footprint for the technical operations that support development and validation of processes and controls for the manufacture of its ex-vivo lentiviral gene therapy products. Orchard’s pipeline currently includes clinical and pre-clinical stage autologous, ex-vivo lentiviral gene therapies for primary immune deficiencies and inherited metabolic disorders. OTL-101, for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID) is in late-stage development and is anticipated to progress to a Biological License Application with the FDA in 2018.
Financial terms:
Latest news:
Is general: Yes
